December 11, 2025 · Form 4 insider transaction
Cormorant Asset Management, LP sold 30,029 shares of CORBUS PHARMACEUTICALS HLDGS at $11.46 per share, a transaction worth $344.0K. The trade was recorded as open-market sale and disclosed on an SEC Form 4, filed 4 days after the transaction.
The reported price represents the weighted average sale price of Common Stock (the "shares") sold in a series of open market transactions on the transaction date at prices ranging from $11.20 to $12.15 per share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of the shares reported herein were sold by the Master Fund.; Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as the general partner of the Master Fund. Bihua Chen serves as the managing member of Cormorant, GP LLC and the Master Fund. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.